Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12620000094976
ACTRN12620000094976
Recruiting
Phase 2

Botulinum toxin for the treatment of anal fistulae - a double blinded randomized trial

Dept Surgery, Deakin University0 sites50 target enrollmentFebruary 4, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsAnal fistulaOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Anal fistula
Sponsor
Dept Surgery, Deakin University
Enrollment
50
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 4, 2020
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Dept Surgery, Deakin University

Eligibility Criteria

Inclusion Criteria

  • •Complex anal fistula with Seton drain in situ

Exclusion Criteria

  • •Patients with known Crohn’s disease of anorectal malignancy.
  • •Patients with rectovaginal or anovaginal fistulae.
  • •Patients with known generalised musculoskeletal disease.
  • •Patients with known sensitivity to Botox.
  • •Pregnant or breast\- feeding women.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
N/A
Botulinum Toxin Type A in the Treatment of Chronic Anal FissureChronic Anal Fissure
NCT05598164State Scientific Centre of Coloproctology, Russian Federation140
Completed
Phase 2
Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/ Interstitial Cystitis.
NL-OMON31587Vrije Universiteit Medisch Centrum12
Active, Not Recruiting
N/A
Botulinum toxin A intravesical injections in the treatment of Bladder Pain Syndrome/Interstitial CystitisInterstitial Cystitis (IC) is a syndrome characterized by bladder pain associated with urgency, frequency, nocturia, dysuria and sterile urine. The patho-physiology remains largely unclear. No universally, effective, treatment exists. Botulinum toxin-A (BTX-A) inhibits the release of acetylcholine at the presynaptic cholinergic junction resulting in temporally muscle relaxation and bladder desensitisation. We explore the effects of intravesical injections with BTX-A in the treatment of IC.
EUCTR2007-005164-27-NLresearch office urology VUmc12
Active, Not Recruiting
Phase 1
Intravesikal instillation af Botulinum toxin type A til patienter med urge urininkontinens
EUCTR2008-006526-34-DKGynækologisk-obstetrisk afd. G, Glostrup Hospital20
Completed
N/A
Intragastric injection of botulinum toxin A for the treatment of obesityobesity
JPRN-UMIN000020931Juntendo University Hospital Department of Gastroenterology30